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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is an established curative treatment for patients
with chronic myeloid leukemia (CML) [1]. A recent ran-
domized study suggested that long-term outcome was
improved when cyclophosphamide (Cy) was combined with
high-dose oral busulfan (Bu) rather than with total body
irradiation in the pretransplantation conditioning regimen
[2,3]. Although the oral BuCy2 regimen is generally well
tolerated, it has been criticized for not being immunosup-
pressive enough to reproducibly permit engraftment, espe-
cially when partially mismatched or matched unrelated
marrow donors are used [4,5]. Low Bu systemic exposure
(Bu-SE), measured as Bu area under the plasma concentra-
tion versus time curve (AUC), has been correlated with
increased risks of graft rejection and leukemic relapse [5,6].
Further, high Bu-SE has been associated with serious
hepatic veno-occlusive disease (VOD) [7-11] and neuro-
logic toxicity (grand mal seizures) [10,12]. These data have
been derived from studies of Bu pharmacokinetics (PK)
after oral drug administration, in which erratic intestinal
absorption leads to highly variable bioavailability and
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ABSTRACT
Complete bioavailability of IV busulfan (Bu) provides dose assurance by reducing the interdose and interpatient
variability in Bu systemic exposure (Bu-SE) associated with the oral formulation. We hypothesized that Bu-SE, rep-
resented by the area under the plasma concentration versus time curve (AUC), would correlate with treatment out-
come after allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myelogenous leukemia (CML).
Therefore, we analyzed the risk of death, incidence of regimen-related toxicity, and incidence of acute GVHD
(aGVHD) as functions of the per dose IV Bu AUC in 36 CML patients who received a HSCT from an HLA-
matched family donor after the IV BuCy2 regimen. Per-dose Bu AUCs were calculated for each subject using data
obtained for doses 1, 5, 9, and 13. Toxicity was evaluated using the modified National Cancer Institute criteria.
Because no patient developed veno-occlusive disease, increased serum bilirubin was used to characterize hepatotox-
icity. We found that the probabilities of developing gastrointestinal toxicity (P = .01), hepatotoxicity (P < .01),
mucositis (P = .09), and aGVHD (P < .01) all increased with increasing AUC. Further, the risk of death was signifi-
cantly lower for patients having a per-dose AUC between approximately 950 and 1520 µMol-min, whereas the risk
increased sharply with either lower or higher AUC values. These data suggest that an optimal Bu therapeutic win-
dow, based on per-dose AUC, exists. Given the ability of IV Bu to provide a more consistent per-dose AUC, these
results should be useful in designing future IV Bu-based treatment protocols for stem cell transplantation.
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produces wide inter- and intra-individual variations in SE
as represented by the AUC [13,14].
We now have used intravenous (IV) Bu [15,16] in a modi-
fied BuCy2 regimen [17] as pretransplantation preparative
therapy for patients with CML, ﬁrst in a ﬁxed-dose regimen
[17] and then with PK-directed dosing, targeting a per-dose
AUC of 1250 µMol-min (±20%) in an attempt to optimize the
antitumor effect and minimize serious toxicity. Here we report
correlations found between Bu-SE, as characterized by Bu
AUC, and patient outcomes, including survival time, gastroin-
testinal (GI) toxicity, mucositis, hepatic toxicity, and acute
graft-versus-host disease (aGVHD). The survival time and
AUC data were used to deﬁne an optimal therapeutic window
for Bu-SE expressed as a per-dose Bu AUC when IV Bu is
used in the IV BuCy2 regimen prior to allogeneic HSCT. For
the 26 patients who achieved Bu-SE inside this window, which
is approximately 950 to 1520 µMol-min, a signiﬁcantly lower
death rate was documented than that of the 10 patients whose
AUC was either below 950 or above 1520 µMol-min.
Although these numerical values are based on a small sample
with only 11 deaths among 36 patients, they suggest that an
optimal therapeutic window for a delivered Bu dose exists.
These results should be useful in designing future IV Bu-
based treatment protocols for stem cell transplantation.
PATIENTS AND METHODS
Eligibility Criteria
Patients were required to have Ph chromosome–positive
(Bcr/Abl-positive) CML, a physiological age between 15 and
55 years, Zubrod performance status < 2, normal (or with
clinically nonsigniﬁcant deviations from normal) renal and
hepatic function (serum creatinine ≤ 1.5 mg/100 mL, biliru-
bin ≤ 1.0 mg/100 mL, serum glutamic-pyruvic transaminase
[SGPT] ≤ 3× the upper normal limit), cardiac left ventricu-
lar ejection fraction ≥ 50%, pulmonary function tests
including forced expiratory volume in 1 minute (FEV1.0) and
diffusing capacity of lung for carbon monoxide (DLCO) ≥
50% of predicted, negative serology for hepatitis B and
human immunodeﬁciency virus, and an overall life expectancy
of at least 12 weeks. Patients were also required to have
either marrow or granulocyte colony-stimulating factor
(G-CSF)-mobilized peripheral blood progenitor cells from
an HLA-matched related donor available. All patients gave
written informed consent to treatment and PK studies in
accordance with institutional guidelines.
Preparatory Regimen
The treatment was modiﬁed from that of Tutschka et al
[17] and has been previously described [18]. IV Bu 0.8 mg/kg
ideal body weight was given over 2 hours every 6 hours for
16 doses by controlled-rate infusion, followed by Cy
60 mg/kg IV over 1 hour on each of 2 consecutive days.
After a day of rest, HSCT was performed. As an alternative
to the ﬁxed-dose Bu, later patients received Bu at 1.0 mg/kg
IV over 2 hours for 2 doses while an initial estimate of Bu-SE
(AUC) was made using ﬁrst-dose Bu plasma-concentration
versus time data. If needed, 1 PK-guided dose adjustment
was performed at dose 3, and that dose was used for the
remaining 13 doses of a 16-dose regimen to achieve a tar-
geted AUCss of 1250 µMol-min (±20%). Additional blood
samples were drawn around doses 5 and/or 9 and 13 to con-
ﬁrm that the dose adjustment resulted in a Bu AUC within
the targeted AUC interval. The IV Bu (Busulfex [busulfan]
Injection, Orphan Medical, Minnetonka, MN) [15,16] was
diluted in normal saline to 0.5 mg/mL and infused through
a central venous catheter. Patients on the last protocol who
received 1.0 mg/kg for 2 doses and who had significant
overweight (>20% above ideal weight) were dosed according
to adjusted ideal body weight. For patients with up to 120%
of ideal body weight, the actual weight was used. For
patients who weighed more than 120% of ideal weight, the
difference between actual and ideal weight was multiplied by
0.5, and this difference was added to the ideal weight and
used as the ﬁnal dosing weight for the ﬁrst 2 doses. From
dose 3 and on, the dosing was then based on PK parameters.
Supportive Care
Phenytoin was administered as seizure prophylaxis
before and during Bu treatment in all patients. Mesna,
antiemetics, blood components, and other supportive care
measures were used per institutional guidelines. Recombi-
nant G-CSF (5 µg/kg per day) was started on HSCT trans-
plantation day +7 and continued until the absolute neu-
trophil count (ANC) exceeded 3.5 × 109/L. The prophylaxis
against GVHD was based on tacrolimus in combination
with low-dose methotrexate [19].
Evaluation of Therapy
The clinical endpoints of the study included regimen-
related toxicity (GI toxicity, hepatotoxicity, mucositis),
engraftment, aGVHD, overall survival, and disease-free sur-
vival. Engraftment was deﬁned as ANC > 0.5 × 109/L. Infor-
mative cytogenetic, fluorescence in situ hybridization
(FISH) (regarding sex mismatched donor-recipient pairs)
and/or restriction fragment length polymorphism (RFLP)
data were collected to support the clinical impression of
engraftment. Clinical remission was defined as normaliza-
tion of marrow morphology and peripheral blood counts,
disappearance of the Ph-chromosome with conventional
cytogenetic technique, and disappearance of the Bcr-Abl
transcript according to reverse transcription–polymerase
chain reaction on bone marrow samples obtained on days
+30 and/or +100 after transplantation and thereafter as indi-
cated. Relapse and progressive disease were deﬁned by the
first day of detection. Survival was defined by the day of
death with the cause of death noted. Disease-free survival
was deﬁned as the time to death or ﬁrst relapse from contin-
uous clinical remission, with the times of relapse and death
censored at last follow-up. During hospitalization, all
patients were monitored daily for adverse events and hema-
tologic parameters, and clinical chemistry parameters were
evaluated at least twice weekly. After discharge and up to
HSCT day +100, all patients were followed for treatment-
related toxicity (weekly), for the quality of engraftment, and
for relapse. After HSCT day +100, disease status and sur-
vival were followed at least quarterly for the ﬁrst year and
then at gradually increasing intervals.
Hepatic VOD was diagnosed based on clinical examina-
tion and laboratory findings [20]. The evaluation of other
toxicities was done according to the modiﬁed National Can-
cer Institute (NCI) criteria.
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Bu Pharmacokinetic Assessment and Prospective
Dose Adjustment
Blood samples (10 mL) for Bu analysis were drawn in
conjunction with the first, fifth, and/or ninth infusions at
the following times: immediately prior to drug infusion; at
15, 30, and 45 minutes after the start of infusion; at 5 min-
utes before the end of infusion (peak; “end of infusion sam-
ple”); and at 15, 30, 60, 120, 180, and 240 minutes after the
end of the infusion. In addition, a sample was taken immedi-
ately prior to the 13th infusion (“trough”) and 5 minutes
prior to its completion (“peak”). Because Bu was adminis-
tered via a central venous catheter, all blood samples for PK
studies were collected from a peripheral IV line to avoid
possible contamination caused by the proximity between the
ports of the triple-lumen central venous catheter used for
drug administration. The samples were collected and placed
on ice. After centrifugation in a refrigerated centrifuge, the
plasma was cryopreserved at –70°C until analysis with high-
pressure chromatography as described [21]. The Bu peak
concentrations (Cmax) and the corresponding peak time
(Tmax) were observed values. The AUC per Bu dose was cal-
culated by dividing the drug dose by the final Bu plasma
clearance estimate. Parameters such as volume of distribu-
tion of the central compartment, elimination rate constant,
and microconstants were estimated, and steady-state volume
of distribution, half-lives, and clearance were calculated
from the primary parameters. The pharmacokinetic model-
ing was performed using the ADAPT II Software program,
Version 4.0 (BMRS, University of Southern California, Los
Angeles, CA [22]). The ﬁnal Bu plasma clearance was deter-
mined by modeling all (doses 1, 5, and/or 9, and 13) Bu
plasma concentration versus time data.
Statistical Methods
Unadjusted survival probabilities were estimated using
the method of Kaplan and Meier [23]. Unadjusted 2-group
survival comparisons were made using the log-rank test [24].
The Cox proportional hazards regression model [25] was
used to assess the ability of patient characteristics or treat-
ments to predict survival, with goodness-of-fit assessed by
the Grambsch-Therneau test and Martingale residual plots
[26] and smoothed using the lowess method of Cleveland
[27]. Predictive variables were transformed as appropriate
based on these plots. A multivariate Cox model was obtained
by performing a backward elimination with P-value cutoff of
.05, then allowing any variable previously deleted to enter
the ﬁnal model if its P-value was <.05. The death rate as a
function of AUC was estimated using smoothing splines
[28], and a 95% confidence band for this estimated death
rate was obtained by bootstrapping [29]. The optimal thera-
peutic range of AUC values for which patients had the
largest overall survival compared to patients having AUC
values outside the range was found by an exhaustive search.
We considered all possible intervals [L, U] satisfying the
conditions U-L > 200 and L < 1232 < U, because the value
AUC = 1232 minimized the estimated hazard function. For
each interval, the P value of the log-rank test comparing the
survival times of patients with AUC values inside the inter-
val to the times of those outside the interval was computed,
and the optimal interval was that having the smallest
P value, denoted P*. To account for multiple testing, we
adjusted this value by repeating the entire process for each
of 1000 random permutations of the 36 AUC values, with the
adjusted P value deﬁned as the proportion of the 1000 tests
having P< P*. A lowess smooth [27] was used to determine
the manner in which each serious adverse event (SAE) indi-
cator (GI toxicity, mucositis, hepatotoxicity, aGVHD) varied
as a function of AUC. Logistic regression [30] also was used
to estimate the probability of each SAE function of AUC.
All computations were carried out in Splus [30] using stan-
dard Splus functions and the Splus survival analysis package
of Therneau [31].
RESULTS
Patients and Disease Characteristics
Thirty-six patients who consented to both treatment
and PK studies (optional on the fixed-dose variant of the
program) were treated between June 1996 and September
2001. Their demographics are summarized as follows.
Median age was 37 years (range, 21-57 years). There were
slightly more men than women enrolled (26/10). All
patients had Philadelphia chromosome–positive (Bcr/Abl-
positive) CML, and 32 were in first chronic phase (CP),
whereas 4 were in accelerated phase (AP). Twenty-six
patients received bone marrow, and 10 patients had a
peripheral blood progenitor cell graft.
Toxicity
All patients received the IV BuCy2 regimen as pre-
scribed, and in no case was the treatment discontinued or
interrupted because of side effects. All adverse events were
consistent with what had been reported with the use of the
oral BuCy2 regimen [17] or of other pretransplantation
conditioning regimens; the administration of IV Bu brought
no new, unexpected toxicity. No grade 4 regimen-related
toxicity was recorded, and we detected no central nervous
system or lung toxicity among these patients.
Patients with organ-specific toxicity of the GI tract
included 10 patients experiencing grade 2 mucositis and
7 patients experiencing grade 3 mucositis (47%), whereas
6 patients had grade 3 diarrhea (17%). In the absence of
VOD, hepatotoxicity was evaluated as the maximum serum
bilirubin recorded in the time interval up to day 30 post-
transplantation: 3 patients developed grade 2 liver toxicity
(bilirubin, 1.1-2.9 mg/100 mL) and 7 patients had grade 3
(bilirubin, 3.0-10 mg/100 mL). Aside from rapidly reversible
increases in bilirubin (within 10 days), no other signs of seri-
ous liver toxicity were recorded, and no liver biopsies were
performed.
Engraftment and Chimerism
All patients showed engraftment at a median of 12 days
posttransplantation. The time to engraftment was not
signiﬁcantly different between patients who received marrow
(median, 13 days; range, 11-20 days) and those who received
peripheral blood progenitor cells (median, 12 days; range,
12-16 days). Median time to recovery to 20,000 platelets/µL
was 19 days (range, 10-53 days). The development of donor-
derived hematopoiesis was further documented by cytogenetic
markers and RFLP studies. Informative data were available
from all patients at 1 and/or 3 months posttransplantation.
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All patients achieved 100% donor chimerism. No patient
had autologous hematopoietic recovery documented, and no
one reverted to host-derived hematopoiesis unless underly-
ing leukemia recurred.
Graft-versus-Host Disease
aGVHD was documented in 12 patients (33%), of
whom 4 had grade II and 8 had grade III disease. No one
developed grade IV aGVHD. No patient died of GVHD
prior to BMT day +100, but 8 patients (22%) died of
chronic GVHD (cGVHD) or its secondary complications
beyond BMT day +100.
Deaths
Eleven of the 36 patients died during the study. Eight,
4 of whom had AUC values >1521 Mol-min (see below),
died of complications of cGVHD. The remaining 3 patients
died of recurrent disease (AUCs of 816 [AP], 866 [CP], and
1061 [CP] µMol-min).
PK Steady-State Parameters
Complete PK proﬁles were assessed at Bu doses 1, 5, 9,
and/or 13. Additionally, peak and trough drug concentra-
tions were always obtained at dose 13 if a whole proﬁle had
been obtained at dose 9. The analyses were performed on
blood samples obtained from all 36 patients entered in the
protocols. At steady-state, the population median AUC was
1265 µMol-min (range, 816-1,905 µMol-min), the mean
half-life (T1/2) was 2.44 hours (range, 1.80-3.15 hours), and
the mean Bu plasma clearance was 2.54 mL/min per kg
(range, 2.1-3.4 mL/min per kg). Clearance and T1/2 esti-
mates did not change substantially from dose 1 to steady
state (dose 5 or 9). The last 11 patients received Bu at an
initial dose of 1.0 mg/kg infused over 2 hours every 6 hours
with an initial estimate of Bu AUC determined around the
ﬁrst dose. Doses 3 through 16 were adjusted as necessary to
achieve a target per-dose AUCss of 1250 µMol-min (±20%).
Estimation of Bu plasma clearance and AUC were also
obtained at doses 5 and 9 and/or 13 to assess the result of
the respective dose adjustments. No further dose adjust-
ments were performed after Bu dose 3, except in 1 patient
who unexpectedly had a signiﬁcantly lower clearance calcu-
lated after dose 5, with a resulting high AUC (1680 µMol-
min). All other patients reached the target window for dose
5, and all 11 patients were in the target window by the all-
dose AUCss estimates. The individual per-dose AUC meas-
urements for doses 1 and 5 and the average all-dose AUC
(dose 13) for each of these patients are shown in Figure 1.
PK and Regimen-Related Toxicity
There was a strong correlation between Bu-SE, quantiﬁed
by Bu plasma AUC, and regimen-related SAEs. These SAEs
included mucositis, GI toxicity, hepatotoxicity, and aGVHD.
For statistical analyses, the SAEs were coded as binary indica-
tors of the severity levels: mucositis = 3, GI toxicity = 3, hepa-
totoxicity ≥ 2, and aGVHD ≥ 2. The distributions of these
events among the 36 patients are shown in Table 1.
Figure 1. Per-dose Bu AUC estimates from the last 11 patients, who received 1.0 mg/kg doses infused over 2 hours every 6 hours with PK assessment
at the ﬁrst dose. Doses 3 through 16 were then individualized, with the aim of an AUCss of 1250 µMol-min (±20%). The PK assessments were repeated
at doses 5 and 9 and/or 13 to assess the results of respective dose adjustments. No further dose adjustments were performed after Bu dose 3, except in 1
patient whose clearance estimate changed dramatically from dose 1 to dose 5.
Table 1. Distribution of SAEs
Mucositis GI Toxicity Hepatoxicity GVHD
No. of events (%) 7 (19.4%) 6 (16.7%) 10 (27.8%) 12 (33.3%)
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Figure 2 illustrates the relationship between AUC and
each type of SAE and shows that the probability of each
SAE, including the 3 toxicities and clinically significant
aGVHD, increased with AUC.
PK, Survival, and Relapse-Free Survival
A Cox proportional hazards regression model was
obtained by a step-down procedure beginning with the
covariates age, sex, disease stage (chronic/accelerated), and
AUC. Only AUC was a significant predictor of survival,
with the final log hazard of death a quadratic function of
log(AUC). The ﬁtted model is summarized in Table 2.
The estimated hazard of death as a function of AUC,
based on smoothing splines rather than the fitted Cox
model, is illustrated in Figure 3. The observed 11 death
times are marked on the hazard curve. All 36 times of death
or censoring times are given by a rug plot along the hori-
zontal axis, and a lowess smoothed bootstrap 95% confi-
dence interval is given by dotted lines.
Repetition of the analysis for event-free survival, with the
event deﬁned as either death or disease progression, resulted
in a qualitatively similar model (Table 3), but the regression of
survival time on AUC was not statistically signiﬁcant.
Based on the fitted Cox model for survival, one may
predict the probability that a future patient will survive at
least 3, 6, 9, or 12 months, as a function of AUC. These
4 predicted survival probabilities, with accompanying 95%
conﬁdence bands, are shown in Figure 4.
Both the ﬁtted Cox model and the estimated hazard in
Figure 3 suggest that there is an optimal interval of AUC val-
ues that on average yields longer survival time. The optimal
interval, derived as described in Statistical Methods, runs from
about 943 to 1521. The lower interval endpoint, 943, is the
mean of the 2 consecutive data values 905 and 981, because
there are no sample values between this pair. Consequently, if
943 were replaced by any number between 905 and 981, the
resulting optimal AUC interval based on this data set would
be identical. Similarly, the upper endpoint, 1521, is the mean
of the 2 data values 1495 and 1547. Thus, the optimal interval
is roughly 950 to 1520 based on these data. The adjusted
P values of the log-rank tests comparing patient survival and
relapse-free survival in the 2 intervals are .20 and .41, reﬂect-
ing the fact that they are obtained from an intensive multiple
testing procedure, as well as the small sample size.
Figure 2. The adverse effects mucositis (A), GI toxicity (B), hepatotoxicity (C), and aGVHD (D) were analyzed as a function of AUC values. The
correlations were highly signiﬁcant.
Table 2. Fitted Cox Model for Survival
Variable Coefficient Standard Error P
Log(AUC) –129.01 63.99 .04
Log(AUC)2 9.04 4.49 .04
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The Kaplan-Meier curves of the estimated survival
probabilities for patients with AUC values inside versus out-
side the optimal interval are given in Figure 5A for overall
survival and in Figure 5B for disease-free survival. These
analyses together suggest that an AUC interval in the range
of approximately 950 to 1520 µMol-min is optimal for the
use of IV Bu in the IV BuCy2 regimen.
DISCUSSION
Numerous trials have demonstrated that oral BuCy2 is
an efﬁcacious pretransplantation conditioning regimen. PK
studies of oral Bu have yielded important correlates with
clinical outcome: low suboptimal Bu blood levels have been
connected with graft rejection and inadequate posttrans-
plantation leukemia control [5,6], whereas a high Bu-SE
correlated with hepatic and neurologic toxicity [7-13]. Vas-
sal concluded in a review of oral Bu that interindividual
variations in Bu-SE may be in the range of 10- to 20-fold
when using a ﬁxed-dose oral Bu regimen of 1.0 mg/kg [32].
This high variability is likely to influence both toxic and
therapeutic effects and adversely affect the outcome of Bu-
based treatment. Precise and predictable dosing in pre-
transplantation conditioning with Bu is important because
the ideal Bu exposure appears to be conﬁned within a fairly
narrow therapeutic window. Several investigators have
advocated individualized Bu dosing based on PK parame-
ters to overcome the interindividual variations in oral Bu
bioavailability. It was assumed that this strategy would help
to control regimen-related toxicity and increase the overall
treatment safety [8,33,34]. Such an approach is intellectu-
ally appealing, but the problems connected with individual-
ized dosing of a drug that has greatly variable interdose
bioavailability present a significant challenge [13]. This
challenge was demonstrated in several reports from PK-
directed oral Bu dosing trials with the aim of arriving at
AUC values within a predetermined therapeutic window
[35-37]. The varying outcomes of these trials are likely due
to, at least in part, the unpredictable interdose Bu bioavail-
ability [10,13,14].
The development of an IV Bu formulation promised to
overcome the bioavailability problem of oral Bu through
more reliable dose assurance. In the current study, IV Bu
was used at a ﬁxed dose of 0.8 mg/kg per dose based on the
PK similarity of this dose to an oral 1.0 mg/kg dose [21]. All
36 CML patients in our present trial received all of their
scheduled IV Bu doses with good tolerance, without either
VOD or serious neurological toxicity. The side effects expe-
rienced were well-described problems following various
types of myeloablative conditioning therapy for HSCT, and
there was no treatment-related mortality at 100 days. All
patients achieved engraftment as documented with complete
chimerism by RFLP studies, and no occurrence of sec-
ondary graft failure was recorded.
Previous studies performed by our group have demon-
strated that Bu PK parameters such as clearance, AUC, and
T1/2 at steady state after IV Bu [18,21] were similar to those
published PK parameters obtained with the oral drug [9-
13,21]. In patients with different types of hematologic
malignancies, highly reproducible Bu PK parameters have
Table 3. Fitted Cox Model for Event-Free Survival
Variable Coefficient Standard Error P
Log(AUC) –88.41 62.07 .15
Log(AUC)2 6.18 4.36 .16
Figure 3. Log hazard risk function for death calculated as a smoothed Martingale function. Dotted lines represent the 95% conﬁdence intervals.
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been documented after IV Bu drug delivery [18]. This ﬁnd-
ing is important because the ideal Bu-SE, according to the
literature concerning orally administered Bu, should be con-
ﬁned within a narrow therapeutic window. Rather than rely-
ing on empiricism in determining the therapeutic range for
IV Bu, we performed a step-wise model analysis based on
the available PK information and the clinical data.
Simple graphical and logistic regression analyses
demonstrated strong correlations between the AUC and
both toxicity and aGVHD. The non–model-based estimate
of the hazard of death and the Cox model–based estimated
probability of surviving for 1 year after HSCT both sug-
gested the presence of an optimal therapeutic range for
high-dose Bu. These results suggest that precise Bu delivery
may be even more important than previously thought, not
only in relation to regimen-related toxicity, but also in the
development of clinically significant aGVHD and for the
likelihood of being alive beyond 1 year after HSCT. The
determined per-dose Bu AUC range (943-1521 µMol-min)
for patients was computed to give the largest survival advan-
tage compared with the survival of patients having AUC val-
ues outside the range (P = .002). Although this optimal AUC
range, or therapeutic window, is specific to the statistical
method that we have used and this particular patient data
set, which has 11 deaths in 36 patients, a general conclusion
is that an optimal range of AUC values likely does exist.
Moreover, once data become available on PK/AUC and sur-
vival time for future patients treated with IV Bu-based pro-
tocols, we anticipate that the optimal interval from those
data will be numerically similar to that found here. In this
context, it is important to remember that the numeric values
arrived at here represent administration of Bu in a 16-dose
regimen together with Cy. It is also important to recognize
that although the PK information correlated with outcome,
clinical disease stage did not. Thus, 2 of the 4 AP patients
were below the therapeutic range at 816 µMol-min (died of
progressive CML) and 905 Mol-min (died of cGVHD),
whereas 2 AP patients are alive at the time of this writing in
complete remission (AUCs of 1183 and 1486 µMol-min). A
potential correlation between clinical stage and outcome as
has been previously reported can neither be conﬁrmed nor
excluded because of the low number of patients beyond ﬁrst
CP in this study. If the regimen is changed, eg, once-daily
IV Bu is combined with fludarabine or another agent
[38,39], the numerical values for the daily Bu-SE assessed as
AUC will change, and the substitution of Cy with ﬂudara-
bine may further modify the therapeutic range.
Our data suggest that IV Bu administration in the IV
BuCy2 regimen for CML patients is optimized if the
patients are assured a Bu-SE within the pharmacokinetically
determined therapeutic window. This goal can be realized
by a PK-directed dosing approach as demonstrated by the
PK data from the last 11 patients in this study.
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